Effect of Chromium Weight Reduction on Adult Asthma Control (ECWAC)
This phase IV randomized controlled trial is designed to evaluate the effects of chromium picolinate supplementation in obese adults with stable asthma. A total of 60 participants will be recruited from Ain Shams University Hospitals and randomly assigned to receive either 400 mcg of chromium picolinate daily or a matching placebo for 12 weeks, in addition to standard asthma therapy.
The study aims to explore the interaction between metabolic dysfunction and asthma, as obesity-related asthma is often associated with systemic inflammation, insulin resistance, and dyslipidemia. These factors may contribute to poorer asthma control and impaired pulmonary function, and therefore represent potential targets for adjunctive therapeutic interventions such as chromium supplementation.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Study Design and Setting This study is a phase IV randomized controlled clinical trial (RCT) involving 60 adult patients diagnosed with asthma. Participants will be recruited from the outpatient clinic and pulmonary function unit of the Chest Department at Ain Shams University Hospitals.
Study Type: Phase IV randomized controlled clinical trial (RCT) Study Setting: Outpatient clinic and pulmonary function unit, Chest Department, Ain Shams University Hospitals Study Population: Adult patients with asthma, obesity, and diabetes mellitus
Sampling and Randomization Participants will be randomly assigned to study groups using computer-generated randomization sequences. Allocation concealment will be ensured through the use of sealed, opaque envelopes.
Ethical Considerations
The study protocol will be explained clearly to all eligible participants prior to enrollment.
The study will commence only after obtaining approval from the Ethical Committee of the Faculty of Medicine, Ain Shams University.
Written informed consent will be obtained from all participants prior to inclusion.
Participant safety will be prioritized, and all efforts will be made to minimize potential risks.
Confidentiality and anonymity of participant data will be strictly maintained. All participants will have an equal chance of being assigned to either study group.
No deceptive practices will be used during the study. Participants will have the right to withdraw from the study at any time without any consequences.
Study Procedures
All eligible participants will undergo the following assessments:
Demographic Data Collection: Age, sex, smoking status, and body mass index (BMI) Clinical Assessment: Detailed medical history including environmental exposures, potential risk factors, comorbidities, and duration of disease
Concomitant Care All participants will continue receiving standard asthma therapy throughout the study period.
Participants will be instructed to maintain a consistent intake of chromium-rich foods during the study to avoid dietary confounding.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Hieba Gamal Gamal Ezz El Regal, PhD
- Telefonnummer: +2 01002041611
- E-post: hiebagamal24@med.asu.edu.eg
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age: 18-65 years
- Confirmed asthma diagnosis according to GINA criteria (7)
- Asthma stable for at least 4 weeks (no acute exacerbation)
- BMI of 30 kg/m² (obese category)
- Stable inhaled corticosteroid + LABA regimen in the last 4 weeks
- The patient is compliant on his asthma medication
- Willing and able to provide informed consent
- willing to continue in the study, follow investigator instructions
Exclusion Criteria:
- - Recent asthma exacerbation (within the last 4 weeks)
- Any change in asthma medications within 4 weeks
- renal or hepatic disease
- Use of lipid-lowering drugs or supplements in the past 3 months
- Use of Vitamin C, prostaglandin inhibitors, such as aspirin, oxalate, and antacids
- Current pregnancy or lactation
- Known allergy to chromium or adverse reaction to supplementation
- Participation in another interventional study in the past month
- History of heavy metal toxicity or chromium sensitivity
- Being on any weight control diet
- Being on a supplement containing chromium
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: Standard of Care
All participants continue standard asthma therapy and management - Study participants will be instructed to keep their dietary consumption of chromium rich foods constant all over the study period. |
|
|
Experimentell: Chromium Picolinate
Two tablets collectively containing 400 mcg of Chromium picolinate which is equivalent to 49.4 mcg of elemental chromium. Taken once daily for 12 weeks. |
Two tablets collectively containing 400 mcg of Chromium picolinate which is equivalent to 49.4 mcg of elemental chromium. Taken once daily for 12 weeks. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in asthma control
Tidsram: from baseline to 12 weeks
|
Change in Asthma Control Test (ACT) Score (points; range 5-25)
|
from baseline to 12 weeks
|
|
Spirometry
Tidsram: from baseline to 12 weeks
|
Forced Expiratory Volume in 1 second (FEV₁) - L or % predicted
|
from baseline to 12 weeks
|
|
Frequency of rescue medication use
Tidsram: from baseline to 12 weeks
|
Frequency of Asthma Inhalers used
|
from baseline to 12 weeks
|
|
Asthma exacerbation frequency
Tidsram: from baseline to 12 weeks
|
Asthma exacerbation frequency
|
from baseline to 12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Lipid Profile
Tidsram: From baseline to 12 weeks
|
Change in fasting total, HDL, LDL Cholesterol in addition to the triglycerides
|
From baseline to 12 weeks
|
|
Anthropometric Measurements
Tidsram: From baseline to 12 weeks
|
Change in Body Mass Index (BMI) Unit of Measure: kg/m²
|
From baseline to 12 weeks
|
|
Incidence of Treatment-Emergent Adverse Events
Tidsram: Monthly from baseline to 3 months
|
The outcome measure will assess the frequency of adverse effects occurring during the study period.
|
Monthly from baseline to 3 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- FMASU R62/2026 (Registeridentifierare: Ain Shams Faculty of Medicine Institutional Review Board)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- ANALYTIC_CODE
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .